Press Releases
InspireMD to Report Fourth Quarter and Fiscal 2018 Financial Results and Provide Business Update on Tuesday, February 19
Conference Call Scheduled for 8am Eastern Time Tel Aviv, Israelâ February 7, 2019 â InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard⢠Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, announced today that it will host a conference call and webcast on Tuesday, February 19,… Read More
InspireMD Announces Presentation of Interim Data from Investigator-Initiated Study Comparing CGuard⢠EPS with a Conventional Open-Cell Carotid Stent
CGuard⢠EPS shows encouraging interim results verses a conventional carotid stent in absence of any adverse clinical events in the CGuard⢠arm  Data presented at the LINC 2019 Congress in Leipzig, Germany Tel Aviv, Israel â January 24, 2019 â InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard⢠Embolic Prevention System (EPS) for the… Read More
InspireMD Announces Two Successful Live Clinical Case Transmissions Featuring CGuard⢠EPS at the Leipzig Interventional Course (LINC) 2019
Cases demonstrate ease-of-use of CGuard⢠EPS in two challenging clinical situations physicians face when treating carotid artery disease Tel Aviv, Israel â January 23, 2019 â InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard⢠Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced that… Read More
InspireMD Announces Results from Initial Clinical Study of The CGuard⢠Embolic Prevention System (EPS) with SmartFitTM Technology
âInitial Clinical Study of the New CGuard⢠EPS MicroNetâ˘ÂŽ Covered Carotid Stent: âOne Size Fits Allââ presented at the LINC 2019 Congress Tel Aviv, Israelâ January 22, 2019 â InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard⢠Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease,… Read More
InspireMDâs CGuard⢠Embolic Prevention System to be Prominently Featured in Live Case Transmissions at LINC, 22nd to the 25th January 2019, in Leipzig, Germany
Several Clinical Presentations, Updates, and Panel Discussions on CGuard EPS to also be presented Tel Aviv, Israelâ January 18, 2019 â InspireMD, Inc.  (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that its CGuard⢠Carotid Embolic Prevention System (EPS) will be featured in two live case… Read More
InspireMD Announces the Distribution of CGuard⢠Embolic Prevention System in South Africa
Growing awareness of CGuard⢠EPS among treating physicians, and resulting demand, were key factors driving entry into the South African market  Tel Aviv, Israelâ January 14, 2019 â InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard⢠Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease,… Read More
InspireMD Receives Noncompliance Notice from NYSE American
Tel Aviv, Israelâ January 11, 2019 â InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard⢠Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced that on January 7, 2019, the Company received a letter from NYSE American LLC (âNYSE Americanâ) stating that it is… Read More
InspireMD Announces Publication of Meta-Analysis Citing Benefits of Next Generation Mesh-Covered Carotid Stent Systems
Analysis includes clinical studies incorporating the Companyâs MicroNetâ˘â˘-covered stent, the CGuard⢠Embolic Prevention System (EPS) Tel Aviv, Israelâ December 18, 2018 â InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard⢠Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced the publication of a meta-analysis of… Read More
InspireMD Announces Positive Long-Term Safety and Efficacy Data from Ongoing CGuard⢠EPS Registries at the Recent 45th Annual Symposium on Vascular and Endovascular Issues, Techniques, Horizons (VEITHsymposium)
Tel Aviv, Israelâ November 29, 2018 â InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard⢠Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced details from several presentations of updated CGuard⢠EPS data at the recent VEITHsymposium in New York. The results of three… Read More
InspireMD Announces Regulatory and Reimbursement Approval of CGuard⢠Embolic Prevention System in Australia Commercial Launch to Occur Immediately
Tel Aviv, Israelâ November 28, 2018 â InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard⢠Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced that its novel CGuard⢠Embolic Prevention System (EPS) has been granted regulatory approval by the Therapeutic Goods Administration (Part of… Read More